Hua Medicine Shanghai saw the highest growth of 0.99% in patent filings in April and 2.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Hua Medicine Shanghai’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Hua Medicine Shanghai has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent grants with nearly 50% of grants. The Israel(IL), South Korea(KR), Peru(PE), and United States(US) patent Office are among the top ten patent offices where Hua Medicine Shanghai is filings its patents. Among the top granted patent authorities, Hua Medicine Shanghai has 50% of its grants in United States(US) and 25% in Canada(CA).
Roche and Johnson & Johnson could be the strongest competitors for Hua Medicine Shanghai
Diabetes related patents lead Hua Medicine Shanghai portfolio followed by hypertension, and diabetic nephropathy
Hua Medicine Shanghai has highest number of patents in diabetes followed by hypertension, diabetic nephropathy, type 1 diabetes (juvenile diabetes), and type 2 diabetes. For diabetes, nearly 100% of patents were filed and 5% of patents were granted in Q2 2024.
For comprehensive analysis of Hua Medicine Shanghai's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

